Teknova Announces Preliminary Third Quarter Financial Results
Estimated revenue and gross margin increased year over year, while adjusted EBITDA remained negative despite an improvement of at least 25%.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Teknova (Nasdaq: TKNO) announced preliminary, unaudited third-quarter 2026 financial results, estimating revenue growth of 19% to 21% from a year earlier.
For the three months ended September 30, 2026, estimated revenue was $12.5 million to $12.7 million. Estimated gross margin was 36.0% to 38.0%, up 500–700 basis points year over year. Adjusted EBITDA, a measure of earnings excluding certain expenses, was estimated at negative $1.2 million to negative $1 million, an improvement of at least 25% year over year. Estimated net loss was $3.694 million to $3.494 million. Cash and short-term investments were estimated at $16.6 million as of September 30.
The results accompanied a preliminary prospectus supplement filing. Estimates remain subject to financial closing and quarterly review, could change materially, and have not been audited or reviewed by the independent accounting firm.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointEstimated third-quarter revenue of $12.5 million to $12.7 million increased 19% to 21% year over year.
- Moderate pointEstimated gross margin of 36.0% to 38.0% expanded 500–700 basis points year over year.
- Moderate pointEstimated adjusted EBITDA of negative $1.2 million to negative $1 million improved at least 25% year over year.
Negative
- Moderate pointEstimated third-quarter net loss was $3.694 million to $3.494 million.
- Moderate pointEstimated third-quarter EBITDA was negative $1.812 million to negative $1.612 million.
- Minor point. Forward-looking: it has not happened yet and may not happen.Preliminary results remain subject to financial closing and quarterly review; changes could be material.
Details
Market move: TKNO -23.41% vs previous close. 3Q26 preliminary financial results
On Oct 20, the day this news came out, the latest delayed price for TKNO is 23.41% below the previous close. Our momentum scanner has recorded 56 alerts for this stock so far that day. The latest delayed price is $5.66.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
- Revenue
- $12.5 million to $12.7 million
- Preliminary estimate for the three months ended September 30, 2026
- Revenue growth
- 19% to 21%
- Estimated change versus the same period in the prior year
- Gross margin
- 36.0% to 38.0%
- Preliminary estimate for the three months ended September 30, 2026
- Gross margin expansion
- 500 to 700 basis points
- Estimated change versus the same period in the prior year
- Adjusted EBITDA
- Negative $1.2 million to negative $1.0 million
- Preliminary estimate for the three months ended September 30, 2026
- Adjusted EBITDA improvement
- At least 25%
- Estimated change versus the same period in the prior year
- Cash and short-term investments
- $16.6 million
- Estimated balance as of September 30, 2026
Previous Earnings Reports
-
Q2 revenue grew 18%, gross margin reached 40.1%, and 2026 revenue outlook was raised.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
prospectus supplement financial
basis points financial
ebitda financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
HOLLISTER, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced in conjunction with its filing of a preliminary prospectus supplement, preliminary unaudited financial results for the three months ended September 30, 2026.
Set forth below are certain preliminary unaudited financial results for the three months ended September 30, 2026 and as of September 30, 2026:
- Revenue for the three months ended September 30, 2026 is estimated to be within the range of
$12.5 million and$12.7 million . - Gross margin for the three months ended September 30, 2026 is estimated to be within the range of
36.0% and38.0% . - Adjusted EBITDA for the three months ended September 30, 2026 is estimated to be within the range of negative
$1.2 million and negative$1 million . - Cash and short term investments as of September 30, 2026 is estimated to be
$16.6 million .
Teknova’s total revenue is estimated to be up
Teknova’s financial statements for the three months and nine months ended September 30, 2026 are not yet available. Accordingly, the information presented above reflects Teknova’s preliminary estimates subject to the completion of Teknova’s financial closing procedures and any adjustments that may result from the completion of the quarterly review of Teknova’s financial statements. As a result, these preliminary estimates may differ from the actual results that will be reflected in Teknova’s financial statements for the quarter when they are completed and publicly disclosed. These preliminary estimates may change and those changes may be material.
Teknova’s expectations with respect to its unaudited results for the periods discussed above are based upon management estimates and are the responsibility of management. Teknova’s independent registered public accounting firm has not audited, reviewed, or performed any procedures with respect to these preliminary results and, accordingly, does not express an opinion or any other form of assurance about them.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.
About Teknova
Teknova makes solutions possible. Since 1996, Teknova has been innovating the manufacture of critical reagents for the life sciences industry to accelerate the discovery and development of novel breakthroughs that will help people live longer, healthier lives. We offer fully customizable solutions for every stage of the workflow, supporting industry leaders in genomics, molecular diagnostics, and emerging therapeutic modalities. Our fast turnaround of high-quality agar plates, microbial culture and cryopreservation media, buffers and reagents, and water helps our customers scale seamlessly from RUO to GMP. Headquartered in Hollister, California, with over 180,000 square feet of state-of-the-art facilities, Teknova’s modular manufacturing platform was designed by our team of scientists, engineers, and quality control experts to efficiently produce the foundational ingredients for the discovery and commercialization of next-generation therapies.
Forward-Looking Statements
This press release contains forward-looking statements under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including statements regarding Teknova’s expectations on the availability of Teknova’s financial statements and completion of financial closing procedures. Forward-looking statements can often be identified by such words as "will," "expects," "plans," "believes," "intends," "estimates," "projects," "continue," "potential" or other similar words or expressions. Forward-looking statements are based on Teknova's current expectations. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially and adversely and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: risks and uncertainties associated with market and other conditions and the satisfaction of customary closing conditions related to the proposed public offering and other risks that are described in Teknova’s most recent periodic reports filed with the Securities and Exchange Commission, including Teknova’s Annual Report on Form 10-K for the year ended December 31, 2025 and subsequent Quarterly Reports on Form 10-Q, including the risk factors set forth in those filings. These forward-looking statements speak only as of the date hereof. Teknova disclaims any obligation to update these forward-looking statements, except as required by applicable law.
Reconciliation of Non-GAAP Financial Measures
Adjusted EBITDA is a non-GAAP financial measure that is not prepared in accordance with GAAP and that may be different from non-GAAP financial measures used by other companies. Our management believes that the use of this non-GAAP financial measure provides an additional tool for investors to use in evaluating ongoing operating results and trends of Teknova. This non-GAAP financial measure should not be considered in isolation from, or as an alternative to, financial measures determined in accordance with GAAP. Adjusted EBITDA is a non-GAAP financial measure equal to net loss, the most directly comparable financial measure based on GAAP, excluding interest expense, income tax expense, depreciation and amortization, and stock-based compensation expense.
The following is a reconciliation of net income, the most directly comparable GAAP financial measure to Adjusted EBITDA:
| ($ in thousands) | Three Months Ended September 30, 2026 (Estimated) | |
| Net loss | ) | |
| Add back: | ||
| Interest expense, net | (259 | ) |
| Provision for income taxes | 34 | |
| Depreciation expense | 1,302 | |
| Amortization of intangible assets | 287 | |
| EBITDA | ) | |
| Other and non-recurring expenses: | ||
| Stock-based compensation expense | 612 | |
| Adjusted EBITDA | ) | |
Contacts:
Investor Contact
Matt Lowell
Chief Financial Officer
matt.lowell@teknova.com
+1 831-637-1100
Media Contact
Jennifer Henry
Senior Vice President, Marketing
jenn.henry@teknova.com
+1 831-313-1259
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What were Teknova's preliminary third-quarter 2026 revenue and gross margin?
Teknova estimated third-quarter 2026 revenue at $12.5 million to $12.7 million and gross margin at 36.0% to 38.0%. Revenue increased an estimated 19% to 21% year over year, while gross margin expanded an estimated 500–700 basis points.
What drove Teknova's estimated third-quarter 2026 financial improvements?
Teknova attributed its estimated gross-margin expansion primarily to revenue growth and its estimated adjusted EBITDA improvement to continued cost discipline.